Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Norgine Germany Switzerland United Kingdom France Netherlands Italy Spain Belgium Austria United States of America

and www.sedar.com.

PEDMARK®,  PEDMARQSI® and Fennec® are registered trademarks of Fennec Pharmaceuticals Inc.

Fennec Contacts:

Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
[phone]

Media:
Lindsay Rocco
Elixir Health Public Relations
[phone]

Norgine Contacts:

Matilde Coruche
Chief People Officer
[e-mail]

Logo - https://mma.prnewswire.com/media/597589/Norgine_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/fennec-pharmaceuticals-and-norgine-enter-into-exclusive-licensing-agreement-to-commercialize-pedmarqsi-in-europe-australia-and-new-zealand-302090953.html